Paul Rogers

Paul Rogers has a diverse work experience spanning several companies and roles. Paul is currently working as a Principal Scientist in Pharmacology at Artiva Biotherapeutics since September 2021. Prior to this, they held the position of a Principal Scientist in Cancer Immunotherapy at Fate Therapeutics Inc from January 2020 to September 2021. Before that, they worked as a Senior Scientist in Bioengineering at Fate Therapeutics Inc from an unknown start date to January 2020.

Paul's earlier work experience includes working as a Senior Research Scientist at Kyowa Hakko Kirin California, Inc. from an unknown start date to 2015. Paul also served as a Postdoc at the La Jolla Institute for Allergy and Immunology, focusing on antigen/TCR signaling and costimulatory molecules on T cell differentiation and survival, from 1996 to 2000.

Prior to their postdoc, Paul was a Postdoctoral Fellow at the University of California, San Diego, where they researched CD4 T cell differentiation, activation, costimulation requirements, and the effect of antigen dose on the development of Th1 & Th2 subsets, from 1993 to 1996.

Paul's early career includes working as a Research Assistant at T Cell Sciences, Inc., where they successfully generated monoclonal antibodies to TCRs for diagnostics, from 1986 to 1987.

Paul Rogers attended UMass Chan Medical School from 1987 to 1993, where they earned a Doctor of Philosophy (PhD) degree in Immunology.